Kymera Therapeutics Reports Q3 GAAP EPS of -$1.32, Missing Estimates
Kymera Therapeutics (KYMR) reported third-quarter GAAP earnings per share of -$1.32, missing analyst expectations by $0.05. Despite the earnings miss, the biotechnology company maintains a strong liquidity position. As of September 30, 2026, Kymera held $1.6 billion in cash, cash equivalents, and investments. Management stated that this substantial cash balance is expected to provide an adequate runway for ongoing operations and development.
Tickers: $KYMR